| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:Lacnotuzumab (anti-M-CSF)
CAS:1831128-32-5
Purity:Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human I Package:5mg Remarks:K10889
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Lacnotuzumab
CAS:1831128-32-5
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Lacnotuzumab
CAS:1831128-32-5
Purity:95% Package:1mg;1g;100g
|
| Company Name: |
Wuhan Chemstan Biotechnology Co., Ltd.
|
| Tel: |
027-65317797 15926423062 |
| Email: |
422450190@qq.com |
| Products Intro: |
Product Name:Lacnotuzumab
Purity:>95%;1mg/ml Package:200ug;500ug;1mg
|
|
| | Lacnotuzumab Basic information |
| Product Name: | Lacnotuzumab | | Synonyms: | Lacnotuzumab;Research Grade Lacnotuzumab;Lacnotuzumab (anti-M-CSF) | | CAS: | 1831128-32-5 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Lacnotuzumab Structure]() |
| | Lacnotuzumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Lacnotuzumab Usage And Synthesis |
| Uses | Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis[1][2]. | | in vivo | Lacnotuzumab neutralizes recombinant and serum-derived forms of cynomolgus CSF-1, but it does not recognize rodent or rabbit CSF-1[2]. | | References | [1] Kuemmel S, et, al. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. Clin Cancer Res. 2022 Jan 1;28(1):106-115. DOI:10.1158/1078-0432.CCR-20-3955
[2] Pognan F, et, al. Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes. J Pharmacol Exp Ther. 2019 Jun;369(3):428-442. DOI:10.1124/jpet.118.254128 |
| | Lacnotuzumab Preparation Products And Raw materials |
|